RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $30

Moomoo NewsJan 7 09:35 ET · Ratings

BofA Securities Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $22

Moomoo NewsJan 7 08:35 ET · Ratings

Regenxbio Price Target Lowered to $22 From $25 at BofA

TipRanksJan 7 07:26 ET

Novartis Reports Positive Results for Intrathecal Zolgensma

Seeking AlphaDec 30, 2024 10:58 ET

PepGen Stock Craters 35% on FDA Clinical Hold

Seeking AlphaDec 16, 2024 09:56 ET

RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $35

Moomoo NewsDec 11, 2024 07:33 ET · Ratings